inosine-pranobex and Herpes-Zoster

Topics: Amantadine; Antiviral Agents; Ascorbic Acid; Dosage Forms; Drug Evaluation; Encephalitis; Hepatitis; Herpes Simplex; Herpes Zoster; Humans; Idoxuridine; Influenza, Human; Inosine Pranobex; Interferons; Levamisole; Rimantadine; Subacute Sclerosing Panencephalitis; Trifluridine; Virus Diseases

Topics: Amantadine; Animals; Benzimidazoles; Chickenpox; Cytarabine; gamma-Globulins; Hepatitis, Viral, Human; Herpes Simplex; Herpes Zoster; Humans; Idoxuridine; Inosine Pranobex; Interferons; Measles; Mumps; Phosphonoacetic Acid; Ribavirin; Rifampin; Rubella; Vaccination; Vaccinia virus; Vidarabine; Virus Diseases

The therapeutic effect of isoprinosine and acyclovir have been studied in 352 and 284 patients with chicken-pox and herpes zoster respectively. The patients were divided into 4 groups: the first one was given palliative treatment only, the second--both palliative and isoprinosine ones, the third--palliative and acyclovir treatment, and the fourth group was given all these. The best therapeutic effect was achieved when acyclovir and isoprinosine was applied jointly, the one of acyclovir alone was less pronounced and that of isoprinosine only was the smallest. According to the authors acyclovir should be the treatment of choice in the very severe and severe cases of chicken-pox and herpes zoster; in the early stage of disease it should be supplemented with isoprinosine and passive immunotherapy.

Topics: Acyclovir; Administration, Oral; Adolescent; Adult; Aged; Chickenpox; Child; Drug Administration Schedule; Drug Therapy, Combination; Female; Herpes Zoster; Humans; Injections, Intravenous; Inosine Pranobex; Male; Middle Aged; Remission Induction; Time Factors

In a double-blind randomised trial, 38 elderly patients with acute herpes zoster received either isoprinosine (IP) or placebo. IP neither shortened the acute phase of herpes zoster nor prevented postherpetic neuralgia. Transient asymptomatic hyperuricaemia affected one third of IP treated patients. Shortcomings in study design and misleading interpretation of results are common in previously published clinical trials of herpes zoster and postherpetic neuralgia. Guidelines for future studies are proposed.

Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Double-Blind Method; Female; Herpes Zoster; Humans; Inosine; Inosine Pranobex; Male; Middle Aged; Neuralgia; Random Allocation

In-vitro and in-vivo evaluation of cellular immune reactions (T-cell subset, E-rosette formation, 2,4-dinitrochlorobenzene, were made in patients with varicella-zoster infection (VZ) and with other intracellular infections. The data demonstrated depressed cellular immunity including a decrease in the number of T-helper cells and a fall in the T-helper/T-suppressor lymphocyte subset ratio to less than 0.7. Three groups of patients with VZ infections were randomly assigned to three regimens: nine patients were given acyclovir alone for five days; ten patients received acyclovir for five days and isoprinosine for ten days; and twelve patients acyclovir for five days and levamisole twice weekly for three weeks. In patients with VZ infections treated with acyclovir and either levamisole or isoprinosine cellular immunity improved faster, while VZ infections in those treated with levamisole healed more rapidly. One patient treated with acyclovir alone had recurrent VZ infection and required a further course of therapy.

Topics: Acyclovir; Adjuvants, Immunologic; Adolescent; Adult; Aged; Dinitrochlorobenzene; Drug Therapy, Combination; Female; Herpes Zoster; Humans; Immunity, Cellular; Inosine; Inosine Pranobex; Levamisole; Male; Middle Aged; Random Allocation; Rosette Formation; T-Lymphocytes; T-Lymphocytes, Helper-Inducer; T-Lymphocytes, Regulatory

A total of 57 herpes zoster patients (28 men and 28 women) were randomly assigned to one of the following four treatments: griseofulvin, 125 mg four times daily; methisoprinol, 1 g four times daily; griseofulvin plus methisoprinol (dosage schedules as above); placebo, four times daily. Griseofulvin had no effect at all, methisoprinol both significantly accelerated drying of vesicles and reduced pain, and the combination of griseofulvin and methisoprinol turned out to be significantly more effective in reducing pain than methisoprinol alone. The present results suggest a new effective treatment for herpes zoster disease.

Topics: Aged; Drug Interactions; Drug Therapy, Combination; Female; Griseofulvin; Herpes Zoster; Humans; Inosine; Inosine Pranobex; Male; Middle Aged; Pain

Topics: Adult; Aged; Clinical Trials as Topic; Follow-Up Studies; Herpes Simplex; Herpes Zoster; Humans; Inosine; Inosine Pranobex; Middle Aged

Topics: Adolescent; Adult; Child; Child, Preschool; Clinical Trials as Topic; Herpes Simplex; Herpes Zoster; Humans; Inosine; Inosine Pranobex; Leukemia; Lymphoma

A double-blind trial comparing isoprinosine with a placebo was conducted in 36 subjects. Improvement of skin lesions was significantly better in the treatment group (p less than or equal to 0.01). Before entering the trial, patients in the treatment group had significantly more severe pain than those in the placebo group (p less than or equal to 0.01), the difference disappeared after treatment. Healing of skin lesions was more rapid in patients treated before the 5th day of the disease (p less than or equal to 0.03). None of the subjects developed post-zoster neuralgia. The clinical effects of the drugs were accompanied by a decrease in serum rosette activity. We consider isoprinosine as an innocuous and effective treatment of herpes zoster.

Topics: Adult; Aged; Double-Blind Method; Drug Evaluation; Female; Herpes Zoster; Humans; Inosine; Inosine Pranobex; Male; Middle Aged

Topics: Adult; Clinical Trials as Topic; Female; Herpes Zoster; Humans; Inosine; Inosine Pranobex; Lymphoproliferative Disorders; Male; Middle Aged; Prospective Studies

By multiple criteria, inosiplex-a reputed stimulator of virus-sensitized lymphocytes-had no demonstrable therapeutic effects in a preliminary controlled study of patients with localized herpes zoster and cancer. Lymphocytes from the six drug-treated patients were no more responsive to varicella-zoster antigen and phytohemagglutinin than were lymphocytes from seven patients who received a placebo.

Topics: Child; Clinical Trials as Topic; Double-Blind Method; Herpes Zoster; Humans; Immunity, Cellular; Inosine; Inosine Pranobex; Neoplasms; Placebos

A 73-year-old female patient presented with asymmetric herpes zoster. She was treated successfully with systemic immunostimulants, vitamin B1 tablets and topical etheric acetyl-salicylic acid solution. No underlying malignancy, immunodeficiency or other systemic diseases could be detected.

Topics: Administration, Oral; Administration, Topical; Aged; Aspirin; Female; HeLa Cells; Herpes Zoster; Herpesvirus 1, Human; Herpesvirus 3, Human; Humans; Inosine Pranobex; Microscopy, Fluorescence; Virus Cultivation

The history of a young female patient is presented. She developed urine retention of sudden onset as a complication of herpes zoster infection manifested in the sacral dermatomes. Symptomatic and antiviral treatments were introduced with full recovery of bladder function. The correct diagnosis of this rare and benign complication of herpes zoster infection can help to avoid unnecessary and invasive examinations.

Topics: Acyclovir; Adolescent; Anuria; Female; Herpes Zoster; Humans; Inosine Pranobex

The reason for giving substances with immunostimulatory properties is to restore or normalize immune functions. Since various human pathogenic viruses can induce immunodepression, the administration of immunostimulants offers a possibility for therapeutic intervention in the immune system. This could be demonstrated. Various virus infections can effectively be influenced by the synthetic immunostimulating agent Inosine Pranobex.

Topics: Antibody Formation; Encephalitis; Female; Herpes Genitalis; Herpes Labialis; Herpes Zoster; Humans; Immunity, Cellular; Immunologic Deficiency Syndromes; Inosine; Inosine Pranobex; Male; Subacute Sclerosing Panencephalitis; Virus Diseases

Topics: Drug Therapy, Combination; Herpes Zoster; Humans; Inosine; Inosine Pranobex; Male; Middle Aged; Rifamycins

Topics: Dengue; Herpes Zoster; Herpesviridae Infections; Humans; Immunity, Cellular; Inosine; Inosine Pranobex; Rosette Formation

Topics: Adult; Aged; Child, Preschool; Drug Evaluation; Female; Herpes Zoster; Humans; Inosine; Inosine Pranobex; Male; Middle Aged; Time Factors

The authors report on their three years' experience in treating 69 patients with herpes zoster of different localization by Inosiplex. The clinical study was carried out in two dermatological centres. Comparison of the results with those of the usual symptomatic treatment leads to the conclusion that the results achieved in the group treated with Inosiplex are significantly better.

Topics: Antibody Formation; Double-Blind Method; Herpes Zoster; Humans; Immunity, Cellular; Inosine; Inosine Pranobex; Random Allocation

Topics: Hepatitis, Viral, Human; Herpes Simplex; Herpes Zoster; Inosine; Inosine Pranobex; Recurrence